AstraZeneca pens $2.1B Sino deal for challenger to Merck’s COPD drug Ohtuvayre

AstraZeneca is paying Sino Biopharmaceutical $200 million upfront for ex-China rights to a late-phase challenger to Merck & Co.’s chronic obstructive pulmonary disease drug Ohtuvayre.